<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" width="1867" height="1458" viewBox="0 0 1867 1458">
  <g id="Group_16739" data-name="Group 16739" transform="translate(-136 -55)">
    <text id="Demonstrated_efficacy" data-name="Demonstrated efficacy" transform="translate(136 275)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="23">DEMONSTRATED EFFICACY</tspan></text>
    <text id="Added_benefits" data-name="Added benefits" transform="translate(136 524)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="23">ADDED BENEFITS</tspan></text>
    <text id="AN_oral_standard_in_anaemia_of_CKD" data-name="AN oral standard in anaemia of CKD" transform="translate(136 729)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="23">AN ORAL STANDARD IN ANAEMIA OF CKD</tspan></text>
    <text id="EVRENZO_can_help_your_patients_achieve_and_maintain_their_target_Hb_levels_by_providing_a_coordinated_erythropietic_response1_EVRENZO_sustained_Hb_levels_without_dose_escalation_irrespective_of_inflammatory_status2_Patients_treated_with_EVRENZO_use_less_I" data-name="EVRENZO can help your patients achieve and maintain their target Hb levels by providing a coordinated erythropietic response1
EVRENZO sustained Hb levels without dose escalation, irrespective of inflammatory status2
Patients treated with EVRENZO use less I" transform="translate(165 343)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="23">EVRENZO can help your patients achieve and maintain their target Hb levels by providing a coordinated erythropietic response</tspan><tspan y="23" font-size="18.666" baseline-shift="10.66559989886036">1</tspan><tspan x="0" y="67">EVRENZO sustained Hb levels without dose escalation, irrespective of inflammatory status</tspan><tspan y="67" font-size="18.666" baseline-shift="10.66559989886036">2</tspan><tspan x="0" y="111">Patients treated with EVRENZO use less IV iron than those treated with ESA</tspan><tspan y="111" font-size="18.666" baseline-shift="10.66559989886036">1,3</tspan></text>
    <text id="Oral_administration1_means_patients_can_avoid_parenteral_therapy_The_convenience_of_treatment_just_3_days_a_week1_4" data-name="Oral administration1 means patients can avoid parenteral therapyThe convenience of treatment just 3 days a week1,4" transform="translate(165 588)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="23">Oral administration</tspan><tspan y="23" font-size="18.666" baseline-shift="10.66559989886036">1</tspan><tspan y="23" xml:space="preserve"> means patients can avoid parenteral therapy</tspan><tspan x="0" y="67">The convenience of treatment just 3 days a week</tspan><tspan y="67" font-size="18.666" baseline-shift="10.66559989886036">1,4</tspan></text>
    <text id="EVRENZO_raises_Hb_levels_without_increasing_CV_risk_compared_to_ESA_in_patients_not_on_dialysis_and_those_just_started_on_dialysis1" data-name="EVRENZO raises Hb levels without increasing CV risk compared to ESA in patients not on dialysis and those just started on dialysis1" transform="translate(165 793)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="23">EVRENZO raises Hb levels without increasing CV risk compared to ESA in patients not on dialysis and those just </tspan><tspan x="0" y="67">started on dialysis</tspan><tspan y="67" font-size="18.666" baseline-shift="10.66559989886036">1</tspan></text>
    <text id="The_safety_profile_of_EVRENZO_has_been_evaluated_in_a_clinical_trial_programme_involving_over_6_800_patients_and_was_overall_comparable_to_ESA_for_the_majority_of_safety_variables1_3_5" data-name="The safety profile of EVRENZO has been evaluated in a clinical trial programme involving over 6,800 patients, and was overall comparable to ESA for the majority of safety variables1–3,5" transform="translate(165 886)" fill="#4d4d4f" font-size="32" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="23">The safety profile of EVRENZO has been evaluated in a clinical trial programme involving over 6,800 patients, </tspan><tspan x="0" y="67">and was overall comparable to ESA for the majority of safety variables</tspan><tspan y="67" font-size="18.666" baseline-shift="10.66559989886036">1–3,5</tspan></text>
    <text id="_1._EVRENZO_EU_SmPC_September_2022._2._Provenzano_R_et_al._Nephrol_Dial_Transplant._2021_36_9_:1717_1730._3._Barratt_J_et_al._Nephrol_Dial_Transplant._2021_36_9_:1616_1628._4._Akizawa_T_et_al._J_Am_Soc_Nephrol._2020_31_7_:1628_1639._5._Fishbane_S_et_al._J_" data-name="1. EVRENZO EU SmPC, September 2022.
2. Provenzano R et al. Nephrol Dial Transplant. 2021;36(9):1717–1730.3. Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.4. Akizawa T et al. J Am Soc Nephrol. 2020;31(7):1628–1639.
5. Fishbane S et al. J " transform="translate(136 1056)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="17">1. EVRENZO EU SmPC, September 2022.</tspan><tspan x="0" y="51">2. Provenzano R et al. Nephrol Dial Transplant. 2021;36(9):1717–1730.</tspan><tspan x="0" y="85">3. Barratt J et al. Nephrol Dial Transplant. 2021;36(9):1616–1628.</tspan><tspan x="0" y="119">4. Akizawa T et al. J Am Soc Nephrol. 2020;31(7):1628–1639.</tspan><tspan x="0" y="153">5. Fishbane S et al. J Am Soc Nephrol. 2022;33(4):850–866. </tspan></text>
    <text id="CKD_chronic_kidney_disease_CV_cardiovascular_ESA_erythropoiesis-stimulating_agent_Hb_haemoglobin_IV_intravenous" data-name="CKD, chronic kidney disease; CV, cardiovascular; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous" transform="translate(136 1012)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd, Trade Gothic LT Std"><tspan x="0" y="17">CKD, chronic kidney disease; CV, cardiovascular; ESA, erythropoiesis-stimulating agent; Hb, haemoglobin; IV, intravenous</tspan></text>
    <text id="EVRENZO_provides_an_alternative_treatment_option_for_the_management_of_anaemia_of_CKD1" data-name="EVRENZO provides an alternative treatment option for the management of anaemia of CKD1" transform="translate(136 123)" fill="#007a33" font-size="52" font-family="TradeGothicLTStd-BoldExt, Trade Gothic LT Std" font-weight="700"><tspan x="0" y="38">EVRENZO provides an alternative treatment </tspan><tspan x="0" y="92">option for the management of anaemia of CKD</tspan><tspan y="92" font-size="30.332" baseline-shift="17.331600108114785">1</tspan></text>
    <g id="Group_13735" data-name="Group 13735" transform="translate(31 21)">
      <circle id="Ellipse_3969" data-name="Ellipse 3969" cx="5.5" cy="5.5" r="5.5" transform="translate(105 327)" fill="#007a33"/>
      <circle id="Ellipse_3973" data-name="Ellipse 3973" cx="5.5" cy="5.5" r="5.5" transform="translate(105 371)" fill="#007a33"/>
      <circle id="Ellipse_4118" data-name="Ellipse 4118" cx="5.5" cy="5.5" r="5.5" transform="translate(105 415)" fill="#007a33"/>
    </g>
    <g id="Group_13737" data-name="Group 13737" transform="translate(31 266)">
      <circle id="Ellipse_3969-2" data-name="Ellipse 3969" cx="5.5" cy="5.5" r="5.5" transform="translate(105 327)" fill="#007a33"/>
    </g>
    <g id="Group_13809" data-name="Group 13809" transform="translate(31 471)">
      <circle id="Ellipse_3969-3" data-name="Ellipse 3969" cx="5.5" cy="5.5" r="5.5" transform="translate(105 327)" fill="#007a33"/>
    </g>
    <g id="Group_13810" data-name="Group 13810" transform="translate(31 564)">
      <circle id="Ellipse_3969-4" data-name="Ellipse 3969" cx="5.5" cy="5.5" r="5.5" transform="translate(105 327)" fill="#007a33"/>
    </g>
    <g id="Group_13808" data-name="Group 13808" transform="translate(31 314)">
      <circle id="Ellipse_3969-5" data-name="Ellipse 3969" cx="5.5" cy="5.5" r="5.5" transform="translate(105 327)" fill="#007a33"/>
    </g>
    <g id="Group_16551" data-name="Group 16551">
      <text id="EVRENZO_roxadustat_IS_NOT_APPROVED_FOR_USE_IN_THE_UNITED_STATES" data-name="EVRENZO (roxadustat)
IS NOT APPROVED FOR USE IN THE UNITED STATES" transform="translate(1673 132)" fill="#4d4d4f" font-size="25" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="-123.25" y="18">EVRENZO (roxadustat)</tspan><tspan x="-161.8" y="48">IS NOT APPROVED FOR USE </tspan><tspan x="-136.45" y="78">IN THE UNITED STATES</tspan></text>
      <text id="This_information_is_intended_for_international_audiences." data-name="This information is intended for international audiences." transform="translate(1673 56)" fill="#4d4d4f" font-size="25" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="-153.825" y="18">This information is intended </tspan><tspan x="-149.65" y="48">for international audiences.</tspan></text>
    </g>
    <g id="Group_16553" data-name="Group 16553" transform="translate(36 -24)">
      <text id="EVRENZO_is_only_available_by_prescription." data-name="EVRENZO™ is only available by prescription." transform="translate(100 1278)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="17">EVRENZO™ is only available by prescription.</tspan></text>
      <text id="Prescribing_information_may_vary._Please_refer_to_your_local_prescribing_information." data-name="Prescribing information may vary. Please refer to your local prescribing information." transform="translate(100 1449)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="17">Prescribing information may vary. Please refer to your local prescribing information.</tspan></text>
      <text id="Astellas_Pharma_B.V._Sylviusweg_62_2333_BE_Leiden._For_full_prescribing_information_please_scan_the_QR_code_or_click_here_For_adverse_events_reporting_please_contact_Pharmacovigilance.EST-C_astellas.com" data-name="Astellas Pharma B.V., Sylviusweg 62, 2333 BE Leiden. For full prescribing information, please scan the QR code or click hereFor adverse events reporting, please contact Pharmacovigilance.EST-C@astellas.com" transform="translate(100 1318)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="17">Astellas Pharma B.V., Sylviusweg 62, 2333 BE Leiden. For full </tspan><tspan x="0" y="45">prescribing information, please scan the QR code or </tspan><tspan y="45" text-decoration="underline">click here</tspan><tspan x="0" y="83">For adverse events reporting, please contact </tspan><tspan x="0" y="111">Pharmacovigilance.EST-C@astellas.com</tspan></text>
      <text id="For_more_information_please_consult_the_complete_product_information_for_EVRENZO_EMA_._To_access_it_please_scan_the_QR_code_or_click_here" data-name="For more information, please consult the complete product information for EVRENZO (EMA). To access it, please scan the QR code or click here" transform="translate(935.457 1318)" fill="#4d4d4f" font-size="23" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="17">For more information, please consult the </tspan><tspan x="0" y="45">complete product information for </tspan><tspan x="0" y="73">EVRENZO (EMA). To access it, please </tspan><tspan x="0" y="101">scan the QR code or </tspan><tspan y="101" text-decoration="underline">click here</tspan></text>
      <image id="qr-code1" width="107" height="107" transform="translate(779 1310)" xlink:href="data:image/png;base64,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"/>
      <image id="qr-code2" width="107" height="107" transform="translate(1357 1310)" xlink:href="data:image/png;base64,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"/>
    </g>
    <g id="Group_13729" data-name="Group 13729" transform="translate(82 447)">
      <text id="_" data-name="▼" transform="translate(707 1040)" font-size="21" font-family="LucidaGrande-Bold, Lucida Grande" font-weight="700"><tspan x="0" y="20">▼</tspan></text>
      <text id="EVRENZOTM_is_subject_to_additional_monitoring." data-name="EVRENZOTM is subject to additional monitoring." transform="translate(734 1045)" fill="#4d4d4f" font-size="21" font-family="TradeGothicLTStd-Bd2, Trade Gothic LT Std"><tspan x="0" y="15">EVRENZO</tspan><tspan y="15" font-size="12.249" baseline-shift="6.999300001743786">TM</tspan><tspan y="15" xml:space="preserve"> is subject to additional monitoring.</tspan></text>
    </g>
  </g>
</svg>
